Table of Contents

Highlights of This Issue 1973

SPECIAL FEATURES

CCR 20th Anniversary Commentary

1975 CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come
Sami I. Bashour and Nuhad K. Ibrahim

CCR Translations

1978 PLEKHA5: A Key to Unlock the Blood–Brain Barrier?
Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos
See related article, p. 2138

1981 The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse
Saar Gill
See related article, p. 2020

CCR New Strategies

1984 New Strategies in Glioblastoma: Exploiting the New Biology
Howard A. Fine

Molecular Pathways

1989 Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Lynnette Fernandez-Cuesta and Roman K. Thomas

1995 Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy
Alexander Lin and Amit Maity

Reviews

2001 Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

2009 Genomic Landscape of Human Papillomavirus–Associated Cancers
Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

CANCER THERAPY: CLINICAL

2020 Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
See related commentary, p. 1981

PERSONALIZED MEDICINE AND IMAGING

2029 Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jaswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmer, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blankin, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

2038 Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largiadére

2045 Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Brian Parkin, Peter Ouillette, Mehmet Vildiz, Kamla Saiya-Cork, Kerby Shedden, and Sami N. Malek
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2177</td>
<td>Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach</td>
<td>Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Cornelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk</td>
</tr>
<tr>
<td>2187</td>
<td>RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter</td>
<td>Steven Sorscher</td>
</tr>
<tr>
<td>2188</td>
<td>RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response</td>
<td>Rona Yaeger and Leonard B. Saltz</td>
</tr>
<tr>
<td>2189</td>
<td>Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression</td>
<td></td>
</tr>
<tr>
<td>2190</td>
<td>Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer</td>
<td></td>
</tr>
<tr>
<td>2192</td>
<td>Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors</td>
<td></td>
</tr>
</tbody>
</table>

**LETTERS TO THE EDITOR**

2187 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter

Steven Sorscher

**RETRACTION**

2189 Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

**CORRECTIONS**

2190 Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

2192 Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

**ABOUT THE COVER**

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.